
Targeted Chemo Improves Survival in Early-Stage Lung Cancer
Among patients with stage 1a to 2a nonsquamous non–small cell lung cancer (NSCLC) identified as high risk by a 14-gene molecular assay who received adjuvant chemotherapy, the interim analysis of the international AIM-HIGH trial revealed a substantial …